SML0196
雷西莫特
≥98% (HPLC), powder, TLR7/TLR8 agonist
别名:
4-氨基-2-(乙氧基甲基)-α, R-848, R848, S28463, α-二甲基-1H-咪唑并(4,5-c)喹啉-1-乙醇
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C17H22N4O2
化学文摘社编号:
分子量:
314.38
UNSPSC Code:
51111800
PubChem Substance ID:
NACRES:
NA.77
MDL number:
产品名称
雷西莫特, ≥98% (HPLC)
SMILES string
CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O
InChI
1S/C17H22N4O2/c1-4-23-9-13-20-14-15(21(13)10-17(2,3)22)11-7-5-6-8-12(11)19-16(14)18/h5-8,22H,4,9-10H2,1-3H3,(H2,18,19)
InChI key
BXNMTOQRYBFHNZ-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
protect from light
color
white to tan
solubility
DMSO: 10 mg/mL, clear (warmed to 60 °C)
shipped in
wet ice
storage temp.
−20°C
Quality Level
Application
瑞喹莫德已用于刺激骨髓源性树突状细胞(BMDC)(和B细胞。它也被用作恶性黑色素瘤细胞系B16F10中Toll样受体(TLR7)的配体。
雷西莫特可用于免疫学和癌症相关的细胞信号传导研究。
Biochem/physiol Actions
瑞喹莫德是314.4 Da分子，可在 L. infantum Sp内脏感染期间引发免疫功能。它可以介导粒细胞、巨噬细胞、白细胞和树突状细胞的运输。它是治疗皮肤肿瘤的建议外敷药物，例如光化性角化病(AK)和表浅性基底细胞癌。
雷西莫特(R-848)是一种有效的TLR7/TLR8合成激动剂，具有抗病毒和抗肿瘤活性。
雷西莫特属于咪唑喹啉胺类化合物，具有免疫调节作用。雷西莫特可提高细胞因子的水平，如TNF-α、IL-6和IFN-α。
雷西莫特是toll样受体7和8（TLR-7和TLR-8）的激动剂。
Features and Benefits
《受体分类和信号转导》手册的 细胞因子受体（白细胞介素-1受体/TIR家族） 页面有该化合物的介绍。想要浏览手册的其他页面， 请单击此处。
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
AMPK Promotes Xenophagy through Priming of Autophagic Kinases upon Detection of Bacterial Outer Membrane Vesicles
Losier TT, et al.
Cell Reports, 26(8), 2150-2165 (2019)
Paeonol ameliorates imiquimod-induced psoriasis-like skin lesions in BALB/c mice by inhibiting the maturation and activation of dendritic cells
Meng Y, et al.
International Journal of Molecular Medicine, 39(5), 1101-1110 (2017)
Anette Christ et al.
Cell, 172(1-2), 162-175 (2018-01-13)
Long-term epigenetic reprogramming of innate immune cells in response to microbes, also termed "trained immunity," causes prolonged altered cellular functionality to protect from secondary infections. Here, we investigated whether sterile triggers of inflammation induce trained immunity and thereby influence innate
Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcgammaRIIb and CD19
Szili,D, et al.
MAbs, 6(4), 991-999 (2014)
Resiquimod, a topical drug for viral skin lesions and skin cancer
Meyer T, et al.
Expert Opinion on Investigational Drugs, 22(1), 149-159 (2013)
商品
Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持